Abbott Initiates Voluntary Correction for 3 Million FreeStyle Libre 3 Glucose Sensors Following False Low Reading Reports
核心洞察
Abbott Laboratories has initiated a voluntary correction for approximately 3 million FreeStyle Libre 3 (搜索) and Libre 3 Plus continuous glucose monitoring sensors in the U.S. due to inaccurate low glucose readings.
The manufacturing defect has been linked to 736 severe adverse events globally, including seven deaths worldwide, though no deaths have been reported among American users.
The FDA has classified this as a "device correction" rather than a full recall, with Abbott offering free replacement sensors to affected users while fixing the underlying manufacturing issue.
Abbott Laboratories has announced a voluntary medical device correction affecting approximately 3 million FreeStyle Libre 3 (搜索) and FreeStyle Libre 3 Plus (搜索) continuous glucose monitoring sensors distributed in the United States. The correction addresses a manufacturing defect that causes certain sensors to provide falsely low glucose readings, potentially leading to life-threatening complications for users with diabetes.
Manufacturing Defect Traced to Specific Production Line
According to Abbott's internal analyses, the accuracy issue has been traced to a specific manufacturing line that produced sensors capable of displaying incorrect glucose readings. The company reports that about half of the 3 million affected sensors may already have been used or have expired, reducing the number of potentially problematic devices currently in circulation.
The faulty sensors pose significant risks to users, as inaccurate low glucose readings can cause patients to skip or delay necessary insulin doses. This delay in treatment can result in dangerous blood sugar spikes and other serious complications for individuals managing type 1, type 2, and gestational diabetes.
Global Safety Impact and Adverse Events
The manufacturing defect has resulted in substantial safety concerns worldwide. Abbott has documented 736 severe adverse event reports globally connected to the malfunctioning sensors, including 57 cases reported within the United States. While no deaths have been confirmed among American users, seven fatalities worldwide have been potentially linked to the recalled devices.
The U.S. Food and Drug Administration has classified this action as a "device correction" rather than a full market recall, meaning the affected sensors are not being physically removed from distribution channels. This classification indicates that while the issue requires attention, it does not warrant complete product withdrawal.
Replacement Program and User Action Required
Abbott has implemented a comprehensive replacement program for affected users. Patients can verify whether their sensors are impacted by visiting www.FreeStyleCheck.com and entering their device's serial number. Those with affected sensors can request free replacements through multiple channels, including calling Abbott's customer service at 1-833-815-4273 between 8 a.m. and 8 p.m. ET, or accessing the company's 24/7 live chat service online.
The company emphasizes that the manufacturing issue has been resolved, and replacement sensors will not be subject to the same accuracy problems. Abbott has confirmed that no other products in the Libre family, including readers, mobile applications, or other sensor models, are affected by this correction.
Scope and Limitations of the Correction
The correction specifically targets FreeStyle Libre 3 (搜索) and FreeStyle Libre 3 Plus (搜索) sensors distributed to diabetes patients nationwide. These devices are widely used by individuals requiring continuous glucose monitoring to manage their condition effectively. The correction does not extend to other Abbott glucose monitoring products, which continue to operate normally without accuracy concerns.